Every 8-K that MacroGenics, Inc. (MGNX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MGNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MGNX filings page.
MacroGenics, Inc. (MGNX) restates its unaudited pro forma financials to treat the June 30, 2026 sale of its CDMO manufacturing operations to Bora as a discontinued operation. The transaction generated $119.6 million in cash at closing and an estimated $91.7 million gain on derecognition of the sold assets.
Pro forma as of March 31, 2026, cash and cash equivalents increase to $177.3 million, and total stockholders’ equity rises to $112.9 million. MacroGenics’ continuing operations now exclude contract manufacturing revenue and related costs, with pro forma 2025 revenue of $96.9 million and a net loss from continuing operations of $91.2 million, or $1.44 per share.
The company describes the divestiture as a strategic shift exiting contract manufacturing to focus resources on its pre-clinical and clinical-stage R&D pipeline. Potential additional contingent payments of up to $5 million are tied to future manufacturing milestones and services and are not reflected in the pro forma figures.
MacroGenics, Inc. reported second quarter 2026 results and a major strategic shift to a fully outsourced manufacturing model. The company completed the sale of its GMP drug substance manufacturing operations to Bora for a base purchase price of $122.5 million, receiving $119.6 million in cash at closing and reducing its workforce toward approximately 140 employees while entering a long-term supply agreement with Bora.
Pro forma cash, cash equivalents and marketable securities totaled $327 million as of June 30, 2026, supporting a stated cash runway through 2028. Quarterly revenue rose to $32.8 million, mainly from a $24.5 million Sanofi milestone, and net income was $19.5 million versus a prior-year loss, driven by $89.2 million income from discontinued operations and partly offset by a $52.8 million non-cash loss on extinguishment of a ZYNYZ royalty monetization liability. The pipeline advanced with Phase 1 progress for MGC026, ongoing studies for MGC028 and lorigerlimab, IND clearance for MGC030, and nomination of preclinical TCE MGD032, while the company remains eligible for up to approximately $2.4 billion in future milestones from partners.
MacroGenics, Inc. reported an update on its ongoing Phase 1 study of MGC026, a B7-H3–directed antibody-drug conjugate for advanced solid tumors. Dose escalation from 1 mg/kg to 9 mg/kg q3W has been completed, and a 7.5 mg/kg q3W dose is being evaluated in four tumor-specific cohorts, including squamous cell carcinoma of the head and neck (SCCHN), endometrial cancer, melanoma and soft tissue sarcoma.
The SCCHN cohort, designed under Simon’s two-stage design with a planned 40-patient enrollment, has met the pre-specified Stage 1 response threshold and is now enrolling Stage 2. As of July 8, 2026, 74 patients had been enrolled across dose escalation and cohort expansion. No cases of interstitial lung disease or ocular toxicity had been reported, and evidence of anti-tumor activity was observed in several indications. MacroGenics plans to present dose-escalation and preliminary cohort data at the ESMO 2026 Congress in Madrid, including a poster on MGC026 on October 23, 2026 and a separate poster on lorigerlimab in advanced gynecologic cancers on October 26, 2026.
MacroGenics, Inc. reported that board member Karen Ferrante, M.D. has decided to resign from its board of directors. She notified the board on July 1, 2026, with her resignation effective September 1, 2026. The company states that her decision is for personal reasons and not due to any disagreement related to operations, policies, or practices. MacroGenics publicly thanked Dr. Ferrante for her contributions to the company.
MacroGenics, Inc. completed the sale of its GMP drug substance manufacturing and CDMO operations in Maryland to Bora Pharmaceuticals and Bora Biologics for $122.5 million in cash, subject to customary post-closing adjustments. Net cash proceeds recognized in the pro forma balance sheet are $110.7 million after working capital adjustments and estimated $8.0 million of transaction costs.
The purchaser assumed responsibility for the CDMO operations, including the Rockville manufacturing site and Frederick warehouse, and hired approximately 140 former MacroGenics employees. MacroGenics and Bora also entered into a supply agreement under which Bora will provide process development and drug substance production for MacroGenics’ pipeline.
On a pro forma basis for the year ended December 31, 2025, total revenue excluding the divested contract manufacturing business is $96.9 million, and net income is $46.3 million, compared with a historical net loss of $74.6 million. The pro forma gain on derecognition of the purchased assets is $109.7 million on January 1, 2025 and $106.1 million on March 31, 2026.
MacroGenics, Inc. reported results from its 2026 Annual Meeting of Stockholders. A total of 36,744,013 common shares were present or represented by proxy, about 58% of the 63,560,068 shares outstanding and entitled to vote as of March 27, 2026.
Stockholders elected all four Class I director nominees to new three‑year terms and ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026. Stockholders also approved, on an advisory basis, the compensation of the named executive officers.
In addition, stockholders approved an amendment to the 2023 Equity Incentive Plan to increase the number of common shares available for issuance by 1,250,000, expanding the pool available for future equity-based awards.
MacroGenics reported a first quarter 2026 net loss of $36.8 million on revenue of $20.8 million, while unveiling a major strategic shift in its operations. Revenue grew from $13.2 million a year earlier, driven by higher contract manufacturing and ZYNYZ royalty revenue, while R&D and G&A expenses both declined.
The company agreed to sell its Maryland manufacturing operations to Bora Pharmaceuticals for an expected $122.5 million upfront and expanded monetization of its ZYNYZ royalties with Sagard Healthcare Partners for $60.0 million plus up to $20.0 million more based on 2026 sales. These transactions, together with existing cash of $154.2 million as of March 31, 2026, are expected to extend MacroGenics’ cash runway through 2028 as it focuses on its antibody-drug conjugate and bispecific pipeline.
MacroGenics, Inc. entered into an Asset Purchase Agreement to sell its GMP drug substance manufacturing and CDMO operations in Maryland to Bora Pharmaceuticals for an upfront cash payment of $122.5 million, subject to customary adjustments and closing conditions. The agreement also includes up to $5 million in potential post-closing cash payments tied to manufacturing milestones and professional development services in 2027 and 2028. Bora will assume the Rockville manufacturing site with total capacity of 11,000 liters, the Frederick warehouse, and is expected to hire approximately 140 MacroGenics employees. At closing, MacroGenics and Bora plan to enter a manufacturing and supply agreement, a transition services agreement, and a sublease, with the transaction expected to close in the third quarter of 2026.
MacroGenics, Inc. entered into a first amendment to its ZYNYZ royalty purchase agreement with Sagard Healthcare Partners, providing an additional $60.0 million in cash and bringing the aggregate purchase price to $130.0 million.
In exchange, Sagard’s capped royalty interest on future global net sales of ZYNYZ was revised so that all royalty rights under the Incyte license will revert to MacroGenics once Sagard has received either 1.70x the $130.0 million aggregate purchase price by September 30, 2032, or 2.0x that amount thereafter. MacroGenics is also eligible for a one-time 2026 sales-based milestone payment of up to $20.0 million, which would increase the aggregate purchase price used for the cap. The company retains other economic interests in ZYNYZ, including potential development, regulatory and commercial milestones.
MacroGenics, Inc. announced that the U.S. Food and Drug Administration has removed the partial clinical hold on its Phase 2 LINNET study of lorigerlimab in gynecologic cancers. This allows the company to resume enrolling new participants under a revised protocol with added safeguards for potential blood and heart-related side effects.
The LINNET study is testing single-agent lorigerlimab, a bispecific DART® antibody targeting PD-1 and CTLA-4, in up to about 60 patients with platinum-resistant ovarian cancer or clear cell gynecologic cancers who have received prior therapies. To date, 41 participants have been treated in LINNET and over 300 across lorigerlimab’s Phase 1 and Phase 2 trials. MacroGenics expects to provide a clinical update on the lorigerlimab program around mid-2026.
MacroGenics, Inc. reported 2025 results and outlined key pipeline milestones. Total revenue was $149.5 million, essentially flat with 2024, while a shift toward contract manufacturing drove contract manufacturing revenue up to $52.6 million from $13.1 million.
Research and development expenses fell to $147.2 million and selling, general and administrative costs dropped to $39.2 million, reflecting program pruning and lower stock-based compensation. Net loss widened slightly to $74.6 million, in part because 2024 benefited from a gain on the sale of MARGENZA.
Cash, cash equivalents and marketable securities totaled $189.9 million as of December 31, 2025, and the company projects cash runway into late 2027. MacroGenics highlighted upcoming data: initial Phase 1 results for ADCs MGC026 and MGC028 in 2026, a mid-2026 update from the lorigerlimab LINNET study currently under a partial FDA clinical hold, and a planned third-quarter 2026 IND filing for ADC MGC030. It also noted substantial potential partner milestones tied to programs with Gilead, Sanofi and Incyte.
MacroGenics, Inc. reported that board member Jay Siegel, M.D. has informed the board that he will not stand for re-election as a Class I director at the company’s 2026 Annual Meeting of Stockholders. The company states that his decision is for personal reasons and not due to any disagreement regarding its operations, policies, or practices. MacroGenics thanks Dr. Siegel for his contributions to the company.
MacroGenics, Inc. reported that the U.S. Food and Drug Administration has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab in gynecologic cancers. Under this action, enrollment of new patients is paused, while existing participants may continue to receive the study drug.
The hold follows recent serious safety events in four patients, including Grade 4 thrombocytopenia in two cases, Grade 4 myocarditis in one case, and Grade 4 neutropenia with concurrent septic shock in one case that progressed to a Grade 5 event. To date, 41 participants have been dosed at 6 mg/kg every three weeks across platinum-resistant ovarian cancer and clear cell gynecologic cancer cohorts.
The LINNET trial uses a Simon two-stage design in platinum-resistant ovarian cancer, with a potential expansion from about 20 to 40 patients if a predefined activity threshold is reached, and includes up to 20 patients with clear cell gynecologic cancer. MacroGenics states it is committed to working closely with the FDA to resolve the partial hold and aims to resume enrollment as soon as conditions allow.
MacroGenics, Inc. announced that Stephen Eck, M.D., Ph.D., its Senior Vice President, Clinical Development and Chief Medical Officer, will depart the company effective December 31, 2025, following a mutual agreement reached on November 14, 2025. Oversight of clinical development will be handled on an interim basis by Frank Perabo, M.D., Ph.D., Vice President, Clinical Development, while an executive recruiter conducts a search for a new Chief Medical Officer. Dr. Eck, who joined MacroGenics in July 2020 and led clinical development across multiple studies, will receive payments and benefits for a qualifying termination in accordance with his employment agreement, conditioned on a general release, waiver of claims, and compliance with his restrictive covenants.
MacroGenics (MGNX) reported that it announced financial and operating results for the quarter ended September 30, 2025. The company furnished a detailed press release as Exhibit 99.1 to this Form 8-K. The information in this report, including Exhibit 99.1, is provided as “furnished” under the Exchange Act and is not deemed “filed.”
MacroGenics, Inc. filed a current report to furnish its financial and operating results for the quarter ended June 30, 2025. The company announced these quarterly results on August 14, 2025 and provided the full details in a press release attached as Exhibit 99.1.
The company states that the information in this report, including the press release, is being furnished rather than filed under securities laws. This means it is not automatically subject to certain liability provisions or incorporated into other securities filings unless specifically referenced.
MacroGenics appointed Eric Risser as President, Chief Executive Officer and elected him as a Class I director with a term expiring at the 2026 annual meeting. Mr. Risser, previously the company’s Chief Operating Officer, became the company’s principal executive officer effective August 13, 2025.
The company agreed an amended employment arrangement providing a $625,000 annual base salary, eligibility for annual incentive pay up to 60% of base salary, and a stock option to purchase 550,000 shares at the closing price on the effective date. Termination protections include cash severance (typically 1.0x salary plus 1.0x target bonus prorated, increased to 1.5x for change-of-control scenarios), COBRA premium coverage up to 18 months, and acceleration of unvested equity upon certain change-of-control terminations.